by
Gus Iversen, Editor in Chief | June 08, 2026
Telix Pharmaceuticals and United Imaging Healthcare North America have signed a memorandum of understanding to evaluate a research collaboration focused on integrating imaging systems and radiopharmaceutical workflows for theranostics applications in the United States.
Under the agreement, the Melbourne, Australia-based radiopharmaceutical company and the Houston-based imaging technology manufacturer will assess how United Imaging’s scanner platforms, software, connectivity tools and artificial intelligence capabilities can be combined with Telix’s molecular imaging products and clinical protocols.
The companies said the effort will examine ways to improve integration between imaging systems and radiopharmaceutical workflows, support standardized imaging protocols across clinical sites, and enhance treatment planning and patient monitoring. The collaboration also includes exploring data-driven and AI-enabled clinical decision support tools.
Ad Statistics
Times Displayed: 7122
Times Visited: 16 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
“Theranostics represents a fundamental shift toward more integrated and personalized cancer care,” Jeffrey M. Bundy, president and chief commercial officer of United Imaging Healthcare North America, said in a statement. “Through this collaboration with Telix, we aim to explore how deeply integrated imaging, AI, and radiopharmaceutical workflows can be combined to support routine clinical use at scale.”
Initial work will focus on Telix’s investigational PET imaging agent TLX101-Px, also known as Pixclara (floretyrosine F 18), in the U.S. Planned activities include imaging protocol optimization, development and validation of workflow support tools, and pilot programs targeting specific clinical applications.
TLX101-Px is being developed for the characterization of recurrent or progressive glioma and has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. In April, the FDA accepted Telix’s new drug application for review and assigned a Prescription Drug User Fee Act target action date of Sept. 11, 2026.
According to Telix, TLX101-Px targets L-type amino acid transporters 1 and 2 and is being studied as a potential patient-selection and response-assessment tool for the company’s investigational glioblastoma therapy candidate, TLX101-Tx. The imaging agent has not been approved for marketing in any jurisdiction.
